Bromodomain and Extra-Terminal (BET) Inhibitors Clinical Trials, Results, Patent, Designation& Pipeline Analysis

The study analyzed that the BET inhibitors pipeline comprised 38 drug candidates in different stages of development. The high prevalence of cancer across the globe fuels the extensive research and development for BET inhibitors.

BET inhibitor constitutes that class of drugs, which prevents interactions between BET proteins, and transcription factors and acetylated histone. This results in immunosuppressive and anti-cancer properties of BET inhibitor. Inhibition of BET proteins offered a new therapeutic approach for the treatment of cancer, cardiovascular diseases and other diseases.

Download Free Sample of This Research Report:  https://www.psmarketresearch.com/market-analysis/bet-inhibitors-pipeline-analysis/report-sample

As per the findings of the research, maximum BET inhibitor drug candidates target BRD4 and are being developed to be administered by oral route.

Resverlogix Corp. is developing its drug candidate in highest stage of development for the treatment of diabetes mellitus, coronary artery disease and cardiovascular diseases. The product is also in different phases of development for different indications, such as atherosclerosis and dyslipidemia.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=bet-inhibitors-pipeline-analysis

The research finds that different companies are collaborating for the development of BET inhibitors with better efficacy.

Some of the key players developing BET inhibitors are Resverlogix Corp., GlaxoSmithKline plc, Bristol-Myers Squibb Company and others.

 

Contact:

Mr. Kundan Kumar

Manager – Client Partner

347, 5th Ave. #1402

New York City, NY – 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

%d bloggers like this: